A5025137989- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Immunotherapy and Immune Responses
- Acute Myeloid Leukemia Research
- Viral-associated cancers and disorders
- Multiple Myeloma Research and Treatments
- CNS Lymphoma Diagnosis and Treatment
- RNA Interference and Gene Delivery
- Biosimilars and Bioanalytical Methods
- Immune Cell Function and Interaction
- Childhood Cancer Survivors' Quality of Life
- Histone Deacetylase Inhibitors Research
- Protein Degradation and Inhibitors
- Monoclonal and Polyclonal Antibodies Research
- T-cell and Retrovirus Studies
- Integrated Circuits and Semiconductor Failure Analysis
- Cutaneous lymphoproliferative disorders research
- Virus-based gene therapy research
- Legal and Constitutional Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Advancements in Semiconductor Devices and Circuit Design
- Lung Cancer Treatments and Mutations
Moffitt Cancer Center
2016-2025
University of South Florida
2015-2025
University College London
2024
University Hospitals Birmingham NHS Foundation Trust
2024
University Hospitals Bristol NHS Foundation Trust
2024
Cambridge University Hospitals NHS Foundation Trust
2024
University College London Hospitals NHS Foundation Trust
2024
Newcastle upon Tyne Hospitals NHS Foundation Trust
2024
King's College Hospital NHS Foundation Trust
2024
Rutgers, The State University of New Jersey
2024
Chimeric antigen receptors redirect T cells (CAR-T) to target cancer cells. There are limited data characterizing cardiac toxicity and cardiovascular (CV) events among adults treated with CAR-T. The purpose of this study was evaluate the possible toxicities registry included 137 patients who received Covariates occurrence grade cytokine release syndrome (CRS) administration tocilizumab for CRS. Cardiac defined as a decrease in left ventricular ejection fraction or an increase serum troponin....
Mantle-cell lymphoma is generally incurable. Initial treatment not standardized but usually includes cytotoxic chemotherapy. Lenalidomide, an immunomodulatory compound, and rituximab, anti-CD20 antibody, are active in patients with recurrent mantle-cell lymphoma. We evaluated lenalidomide plus rituximab as a first-line therapy.We conducted single-group, multicenter, phase 2 study induction maintenance phases. During the phase, was administered at dose of 20 mg daily on days 1 through 21...
CD19 CAR T-cell therapy with axicabtagene ciloleucel (axi-cel) for relapsed or refractory (R/R) large B cell lymphoma (LBCL) may lead to durable remissions, however, prolonged cytopenias and infections occur. In this single center retrospective study of 85 patients, we characterized immune reconstitution patients remaining in remission after axi-cel LBCL. Prolonged (those occurring at day 30 following infusion) were common >= grade 3 neutropenia seen 21/70 (30-0%) persisting 3/31 (9-7%) 1...
Treatment of acute lymphoblastic leukemia (ALL) continues to advance, as evidenced by the improved risk stratification patients and development newer treatment options. Identification ALL subtypes based on immunophenotyping cytogenetic molecular markers has resulted in inclusion Philadelphia-like early T-cell precursor that affect prognosis. Ikaros mutations also emerged a prognostic factor. In addition prognostication, options for with have expanded, particularly regard relapsed/refractory...
Abstract High metabolic tumor volume (MTV) predicts worse outcomes in lymphoma treated with chemotherapy. However, it is unknown if this holds for patients axicabtagene ciloleucel (axi-cel), an anti-CD19 targeted chimeric antigen receptor T-cell therapy. The primary objective of retrospective study was to investigate the relationship between MTV and survival (overall [OS] progression-free [PFS]) relapsed/refractory large B-cell (LBCL) axi-cel. Secondary objectives included finding...
The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of ALL subtypes based immunophenotype and cytogenetic/molecular markers; risk assessment stratification risk-adapted therapy; treatment strategies Philadelphia chromosome (Ph)-positive Ph-negative both adolescent young adult patients; supportive care considerations. Given complexity regimens required measures, Panel recommends that patients be treated at a specialized cancer center with expertise in...
PURPOSE Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory mantle cell lymphoma (MCL). This was on the basis of single-arm phase II ZUMA-2 trial, which showed best overall and complete response rates 91% 68%, respectively. We report clinical outcomes with brexu-cel in standard-of-care setting indication. PATIENTS AND METHODS Patients who underwent leukapheresis between August 1, 2020 December...
Obecabtagene autoleucel (obe-cel) is an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy which uses intermediate-affinity CAR to reduce toxic effects and improve persistence. We conducted a phase 1b-2 multicenter study of obe-cel in adults (≥18 years age) with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The main cohort, cohort 2A, included patients morphologic disease; 2B had measurable residual disease. primary end point was overall remission...
Significance The aggregation of mutant proteins is pathologically implicated in a large number neuropathies, including Huntington disease and ALS. Although the appearance protein aggregates known to sequester other proteins, how this results gain-of-function toxicity these diseases unclear. Here, we show that disease-associated causes reversible collapse clathrin-mediated endocytosis (CME) inhibits internalization membrane receptors affect neuronal function. CME inhibition occurs through...
Abstract The novel Bruton’s tyrosine kinase inhibitor ibrutinib has demonstrated high response rates in B-cell lymphomas; however, a growing number of ibrutinib-treated patients relapse with resistance and fulminant progression. Using chemical proteomics an organotypic cell-based drug screening assay, we determine the functional role tumour microenvironment (TME) activity acquired resistance. We demonstrate that MCL cells develop through evolutionary processes driven by dynamic feedback...
The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. However, management relapsed or refractory (R/R) ALL remains challenging is poor. NCCN Guidelines provide recommendations on standard treatment approaches based current evidence. These Insights summarize R/R highlight important updates, a summary panel's...
The authors conclude that the overall rate of documentation is low and results show disparities among specific groups. While greater numbers discussions may be occurring, there need to create interventions improve documentation.
Mantle cell lymphoma (MCL) is a B-cell characterized by cyclin D1 expression. Autologous hematopoietic transplantation (AHCT) consolidation after induction chemotherapy often used for eligible patients; however, the benefit remains uncertain in rituximab era. Herein we retrospectively assessed impact of AHCT on survival large cohort transplantation-eligible patients age 65 years or younger.We studied adults younger with newly diagnosed MCL treated between 2000 and 2015. The primary objective...
Abstract Background Brexucabtagene autoleucel (KTE-X19) is an autologous anti-CD19 CAR T-cell therapy approved in the USA to treat adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (R/R B-ALL) based on ZUMA-3 study results. We report updated outcomes longer follow-up and extended data set along contextualization of historical standard care. Methods Adults R/R B-ALL received a single infusion KTE-X19 (1 × 10 6 T cells/kg). Long-term post hoc subgroup...